Pancreatic Cancer Research

ResearcherUniversité Paris-SaclayActive in the last 2 years

Cristina Smolenschi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7568-6196; OpenAlex author ID A5003504418, A5012527087. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 5 papers · 2025: 3 papers · 2026: 3 papers

Papers 14

  1. Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment. Co-author DOI 10.1016/j.ejca.2025.116160↗
  2. Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. Co-author DOI 10.1016/j.ejca.2026.116227↗
  3. Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116768↗
  4. Precision medicine strategy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.esmoop.2025.105899↗
  5. Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patients. Co-author DOI 10.1080/14796694.2025.2461442↗
  6. The Role of Computed Tomography-Determined Total Tumor Volume at Baseline in Predicting Outcomes of Patients with Locally Advanced Unresectable or Metastatic P… Co-author DOI 10.3390/cancers18010020↗
  7. Clinical and molecular features of early onset pancreatic adenocarcinoma. First author DOI 10.1002/ijc.35135↗
  8. Codon-specific KRAS mutations predict survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2023.100030↗
  9. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2024.05.032↗
  10. Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study. Co-author DOI 10.1186/s12885-024-12016-z↗
  11. Role of molecular biology in the management of pancreatic cancer. First author DOI 10.4251/wjgo.v16.i7.2902↗
  12. Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations. Co-author DOI 10.3390/biomedicines11092569↗
  13. FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? Last author DOI 10.1016/j.ejca.2022.09.016↗
  14. Systemic treatment of pancreatic cancer revisited. Co-author DOI 10.1053/j.seminoncol.2018.12.003↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Antoine Hollebecque · 14 shared papers, 2019–2026 · strength 2.62
  2. Michel Pierre Ducreux · 14 shared papers, 2019–2026 · strength 2.62
  3. Anthony Tarabay · 11 shared papers, 2023–2026 · strength 2.13
  4. Alice Boilève · 11 shared papers, 2023–2026 · strength 2.13
  5. David Malka · 5 shared papers, 2019–2024 · strength 0.74
  6. Nathalie Lassau · 3 shared papers, 2025–2026 · strength 0.61
  7. Antoîne Italiano · 3 shared papers, 2024–2026 · strength 0.52
  8. Aurélien Lambert · 2 shared papers, 2024–2026 · strength 0.44
  9. Fanny Jaulin · 2 shared papers, 2024 · strength 0.30
  10. Thierry Conroy · 2 shared papers, 2019–2024 · strength 0.30
  11. Mélanie Debiais · 1 shared paper, 2026 · strength 0.25
  12. Matthieu Delaye · 1 shared paper, 2026 · strength 0.24
  13. Victor Robic · 1 shared paper, 2026 · strength 0.22
  14. Étienne Rouleau · 1 shared paper, 2025 · strength 0.21
  15. Clara Helal · 1 shared paper, 2022 · strength 0.20
  16. Elissar Moujaess · 1 shared paper, 2025 · strength 0.19
  17. Roland Eid · 1 shared paper, 2025 · strength 0.19
  18. Anna Gueiderikh · 1 shared paper, 2024 · strength 0.19
  19. Maxime Rémond · 1 shared paper, 2024 · strength 0.17
  20. Marc Hilmi · 1 shared paper, 2024 · strength 0.15
  21. Rémy Nicolle · 1 shared paper, 2024 · strength 0.15
  22. Pierre Laurent‐Puig · 1 shared paper, 2019 · strength 0.10
  23. Jean‐Luc Van Laethem · 1 shared paper, 2019 · strength 0.10
  24. Thomas Theodor Werner Seufferlein · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.